National Biotechnology Initiative Act of 2025
- Sponsor
- Rep. Bice, Stephanie I. [R-OK-5]
- Committees
- Education and Workforce Committee (primary)
- Last action
- Apr 9, 2025
Bottom line
This bill creates a comprehensive federal framework to strategically advance U.S. leadership in biotechnology through coordinated research, development, commercialization, and regulatory streamlining across multiple government agencies.
What it actually does
This bill establishes the National Biotechnology Initiative within the Executive Office of the President, creates a National Biotechnology Coordination Office (NBCO) and an Interagency Committee, and mandates extensive biotechnology-related activities across 13 federal agencies. It aims to coordinate federal efforts, streamline regulation, boost research and development, develop the workforce, and enhance national security and economic competitiveness in biotechnology.
Proponents argue
Supporters argue that a coordinated national strategy is essential for the United States to maintain its global leadership in biotechnology, which is critical for national security, economic growth, and addressing societal challenges in health, agriculture, and energy. They contend that the current fragmented approach hinders progress and that this initiative will streamline efforts, accelerate innovation, and ensure a robust domestic workforce and supply chain.
Opponents contend
Critics might argue that creating a new office and interagency committee could lead to increased bureaucracy and duplication of efforts already underway within existing agencies. Concerns could also be raised about the potential for over-centralization of scientific research priorities, the cost of the new initiative, or the balance between regulatory streamlining and necessary oversight for biosafety and biosecurity.
The bill is moderately detailed but clearly structured, allowing an informed reader to understand its core provisions within a reasonable timeframe.
Section 3(a)
Authorization of the National Biotechnology Initiative
This provision formally establishes the National Biotechnology Initiative within the Executive Office of the President. Its purpose is to advance national security, economic productivity, and competitiveness by coordinating and advancing federal activities related to biotechnology. It designates 13 specific federal agencies, plus others deemed appropriate, as participants in this initiative.
Supporters argue
Supporters argue that a unified, national-level initiative is crucial to overcome fragmented efforts and ensure the U.S. remains a leader in biotechnology, leveraging the strengths of diverse agencies.
Critics contend
Some might argue that existing interagency coordination mechanisms are sufficient, and a new, overarching initiative could add layers of bureaucracy without significantly improving outcomes.
Tradeoffs
Balances the need for centralized strategic direction with the autonomy and specialized expertise of individual agencies.
Section 4(b)
Establishment of the National Biotechnology Coordination Office (NBCO)
This section mandates the establishment of the NBCO within the Executive Office of the President within 180 days of enactment. It also requires the President to appoint a Director for the NBCO, who will serve as the principal advisor to the President for biotechnology and administer the Office's functions. The Office is tasked with extensive coordination, planning, and assessment duties across all aspects of the Initiative.
Section 4(b)(3)(F) and Section 4(b)(5)
Regulatory Streamlining Mandate and OMB Intervention
The NBCO is tasked with coordinating the easing of regulatory burdens for well-understood biotechnology products and negotiating interagency agreements to establish clear regulatory pathways. These pathways must include timelines, decision points, data requirements, and clear agency hand-offs. If the NBCO and the Interagency Committee cannot reach timely agreement on a pathway, the Director of the Office of Management and Budget (OMB) is mandated to intervene, identify issues, negotiate an agreement, and recommend necessary rulemaking or guidance changes.
Section 4(b)(4)(B)
Authorization of Appropriations for NBCO Support
This provision authorizes specific appropriations to the Director of the National Science Foundation (NSF) to provide administrative and implementation support for the NBCO. The authorized amounts are $22 million for FY2026, $35 million for FY2027, and $25 million for each of FY2028, FY2029, and FY2030. These funds cover staffing, compensation, physical space, and other overhead costs for the new office.
Section 6
Comprehensive Agency Activities to Advance Biotechnology
This section mandates that each participating federal agency (listed in Section 3(b)) must conduct or support a wide range of activities in coordination with the NBCO, consistent with their mission. These activities span planning, national security, research and development, data management, product commercialization, regulatory streamlining, biosafety and biosecurity, workforce development, bioliteracy, and international partnerships. This includes designating a lead individual at the Assistant Secretary level and participating in subcommittees.
States that Section 1013 of title 5, United States Code (the Federal Advisory Committee Act or FACA), shall not apply to the convening of experts by the NBCO Director.
Section 5(b)
Why it matters:This is standard legislative practice for certain expert groups where the intent is to allow for more flexible and rapid consultation without the procedural requirements of FACA, which can be cumbersome.
Case for: Proponents argue that exempting expert convenings from FACA allows the NBCO to quickly gather specialized advice from the private sector, academia, and other non-federal entities without lengthy administrative processes, enabling more agile policy responses to rapidly evolving biotechnology.
Case against: Critics might argue that FACA exists to ensure transparency, balance, and public accountability in federal advisory bodies. Exempting these groups could lead to less diverse viewpoints, potential conflicts of interest, or a lack of public access to the advice being given to the government.
Estimated impact: Enables the NBCO to form ad-hoc expert groups more easily, potentially accelerating policy development but reducing public transparency and formal oversight of these advisory bodies.
The NBCO is mandated to wind down its activities 20 years after the date of enactment, transitioning to serving as an executive secretariat for the Initiative. This involves transferring authorities, resources, and personnel to the Interagency Committee or other federal elements, while maintaining core coordination functions.
Section 4(b)(6)
Why it matters:This provision aims to ensure the Initiative's long-term sustainability and adaptability by planning for a transition from a dedicated office to a more integrated, secretariat-style coordination mechanism after two decades. It's a common sunset/transition clause.
Case for: Proponents argue that this ensures the Initiative's long-term viability by allowing for an evolution of its coordinating structure, preventing the creation of a permanent, potentially redundant, bureaucracy while retaining essential coordination functions.
Case against: Critics might suggest that a 20-year wind-down period is too long to be meaningful for accountability, or that the transition plan is vague, potentially leading to uncertainty or a loss of institutional knowledge when the office formally changes its structure.
Estimated impact: Shapes the long-term institutional structure and longevity of the National Biotechnology Initiative, ensuring its continued, albeit modified, existence beyond two decades.